<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01193504</url>
  </required_header>
  <id_info>
    <org_study_id>25324</org_study_id>
    <nct_id>NCT01193504</nct_id>
  </id_info>
  <brief_title>Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification</brief_title>
  <official_title>Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovative Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovative Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Lotemax eye drops are at least as effective as
      Pred Forte eye drops, which are the standard of care after cataract surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prednisolone 1%, a topical steroid, is considered standard of care following cataract surgery
      to reduce inflammation. We aim to determine if Lotemax is at least as effective as
      Prednisolone. If so, these findings would demonstrate that physicians have other treatment
      options to consider.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention Of Retinal Thickening</measure>
    <time_frame>1 Year</time_frame>
    <description>OCT (optical coherence tomography) with macular thickening
Incidence of CME ( cystoids macular edema)
BCVA (best corrected visual acuity)
UCVA (uncorrected visual acuity)
Central corneal thickness</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pseudophakia</condition>
  <condition>Cataract Surgery</condition>
  <arm_group>
    <arm_group_label>Pred Forte</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients scheduled to undergo phacoemulsification will be randomized in a 1:1 schedule to receive Pred Forte BID for 4 weeks postop. All patients will receive Xibrom BID for one month and Besifloxacin BID for 7 to 10 days postop.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lotemax</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients scheduled to undergo phacoemulsification will be randomized in a 1:1 schedule to receive Lotemax BID for 4 weeks postop. All patients will receive Xibrom BID for one month and Besifloxacin BID for 7 to 10 days postop.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pred Forte</intervention_name>
    <description>Pred Forte BID for 4 weeks postop</description>
    <arm_group_label>Pred Forte</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lotemax</intervention_name>
    <description>Lotemax BID for 4 weeks postop.</description>
    <arm_group_label>Lotemax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female &gt;18 years of age scheduled to undergo cataract surgery

          -  Patients with systemic diseases will be enrolled only if there are no ocular
             manifestations of their disease (e.g. diabetics with normal retinal exams)

          -  Expected visual outcome of BCVA (best corrected visual acuity)&gt; 20/25 postoperatively,
             as determined by potential visual acuity testing and review of preoperative corneal
             topography and OCT (optical coherence tomography).

          -  Ability to provide informed consent, take study medications as directed, and likely to
             complete all study visits

        Exclusion Criteria:

          -  Known contraindication to any study medication or any of their components

          -  Required use of ocular medications other than the study medications during the study

          -  Evidence of macular disease (Epiretinal membrane, Vitreomacular traction syndrome,
             macular hole) on preoperative OCT (optical coherence tomography)

          -  Presence of significant dry macular degeneration that may impact postoperative visual
             results.

          -  History of retinal vein occlusion or diabetic macular edema, uveitis or any macular
             disease predisposing them to cystoid macular edema or prolonged intraocular
             inflammation.

          -  Posterior capsule rupture, Vitreous loss during surgery or any other complication that
             in the surgeon's opinion, could reduce potential for targeted visual outcome

          -  Anticipated need for mechanical iris dilating devices

          -  Presence of Epithelial Basement Membrane Dystrophy, significant dry eye, significant
             blepharitis, or any other corneal condition that may impact BCVA (best corrected
             visual acuity) postoperatively
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Trattler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Center for Excellence in Eye Care</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Hovanesian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard Eye Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bonnie Henderson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmic Consultants of Boston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenna Piel</last_name>
    <phone>(951)653-5566</phone>
    <email>j.piel@imedsonline.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Harvard Eye Associates</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Earl</last_name>
      <phone>951-653-5566</phone>
      <email>m.earl@imedsonline.com</email>
    </contact>
    <contact_backup>
      <last_name>Annie Christensen</last_name>
      <phone>(951)653-5566</phone>
      <email>a.christensen@imedsonline.com</email>
    </contact_backup>
    <investigator>
      <last_name>John Hovanesian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Center For Excellence in Eye care</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Earl</last_name>
      <phone>951-653-5566</phone>
      <email>m.earl@imedsonline.com</email>
    </contact>
    <contact_backup>
      <last_name>Annie Christensen</last_name>
      <phone>(951)653-5566</phone>
      <email>a.christensen@imedsonline.com</email>
    </contact_backup>
    <investigator>
      <last_name>William Trattler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Buznego, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2010</study_first_submitted>
  <study_first_submitted_qc>September 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2010</study_first_posted>
  <last_update_submitted>June 13, 2012</last_update_submitted>
  <last_update_submitted_qc>June 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2012</last_update_posted>
  <responsible_party>
    <name_title>Dr. William Trattler</name_title>
    <organization>The Center for Excellence in Eye care</organization>
  </responsible_party>
  <keyword>Prevention of Retinal Thickening and CME Following Phacoemulsification</keyword>
  <keyword>Pseudophakia following cataract surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Pseudophakia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Bromfenac</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid</mesh_term>
    <mesh_term>Loteprednol Etabonate</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

